ReviewMolecular diagnosis & therapy2026
LINE-1 Deregulation in Ovarian Cancer: Implications for Diagnosis, Prognosis, and Therapeutic Targeting.
Review in Molecular diagnosis & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is a highly heterogeneous malignancy and remains a major cause of cancer-related mortality, mainly due to late diagnosis and frequent development of therapy resistance. Current diagnostic markers show limited sensitivity for early-stage disease, highlighting the need for novel biomarkers and improved understanding of tumor biology. Epigenetic deregulation is a hallmark of ovarian cancer, characterized by global DNA hypomethylation and focal hypermethylation of tumor suppressor genes. Among hypomethylated genomic regions, long interspersed nuclear elements-1 (LINE-1) represent a large fraction of the human genome and a widely used surrogate marker of global epigenetic instability. LINE-1 elements are normally epigenetically silenced. In ovarian cancer, loss of LINE-1 methylation leads to transcriptional reactivation, expression of ORF1p and ORF2p, and increased retrotransposition activity. These events contribute to genomic instability, DNA damage, insertional mutagenesis, tumor heterogeneity, and clonal evolution. LINE-1 deregulation is also associated with defects in DNA repair pathways, including homologous recombination deficiency, and may influence tumor progression and response to therapy. In addition, aberrant LINE-1 activity has been linked to activation of innate immune and interferon-related signaling pathways, supporting its biological relevance in cancer. Several studies indicate that LINE-1 hypomethylation is associated with aggressive tumor features and adverse clinical outcomes in ovarian cancer. Importantly, repetitive elements, including LINE-1, can be detected in circulating cell-free DNA (cfDNA), providing a technical basis for their evaluation as minimally invasive biomarkers. This review summarizes current knowledge on LINE-1 biology, epigenetic regulation, and functional consequences in ovarian cancer. In addition, we discuss the realistic potential of LINE-1 as a circulating epigenetic biomarker and therapeutic target.
Identifiers
42277396What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.